Despite the therapeutic potential of anti-PODXL mAbs, their further development has been limited by concerns regarding potential on-target off-tumor toxicities, particularly to normal kidney podocytes [4] and vascular and lymphatic endothelial cells [5]. Here, PODXL is linked to neoplasm.